The short answer: hormone therapy increases risk for some cancers, but the size of that increase depends on which hormones you take, how long you take them, and your age when you start

Hormone replacement therapy (HRT) does raise the risk of certain cancers—primarily breast cancer and endometrial cancer—but the increase is modest for most people and must be weighed against the relief HRT provides from severe menopause symptoms. The risk is not the same for all types of hormone therapy. Estrogen alone carries a different risk profile than estrogen combined with progestin. Starting HRT at a younger age and taking it for longer periods generally increases risk more than short-term use in older women.

The evidence comes from large studies that followed thousands of women over many years, most notably the Women's Health Initiative (WHI), which began in 1991 and produced results that shifted how doctors prescribe hormones. What those studies show is real but often smaller than people fear—and the decision to use HRT involves weighing cancer risk against other health effects and quality of life.

Key Takeaways

  • Combined estrogen-progestin therapy (the most common form) raises breast cancer risk by roughly 20 to 30 percent after five years of use, meaning the absolute risk remains low for most women but is measurable.
  • Estrogen-only therapy increases endometrial cancer risk significantly but does not raise breast cancer risk, and is typically offered only to women who have had a hysterectomy.
  • Risk increases with duration of use and is highest in women who start HRT before age 60 or within ten years of menopause onset.
  • The increased cancer risk begins to decline after stopping HRT, though some elevation may persist for several years.
  • Other health outcomes—such as reduced bone fractures, lower cardiovascular risk in some age groups, and symptom relief—must be considered alongside cancer risk when deciding whether HRT is right for you.

What the major research studies found

The Women's Health Initiative enrolled over 160,000 postmenopausal women starting in 1991 and tracked their health outcomes. The study was stopped early in 2002 when researchers found that women taking combined estrogen-progestin therapy had a higher rate of breast cancer, blood clots, and stroke than those taking placebo. This finding surprised many doctors and patients who had assumed hormone therapy was protective.

The WHI found that after five years of combined HRT use, breast cancer risk rose by about 26 percent compared to women not taking hormones. That sounds large, but it means that out of 10,000 women taking combined HRT for five years, roughly 38 would develop breast cancer versus 30 who would develop it without HRT—a difference of 8 cases. For endometrial cancer in women taking estrogen alone, the risk roughly doubled, which is why estrogen-only therapy is now reserved for women without a uterus.

Later analysis of WHI data and other long-term studies showed that risk varies significantly by age at start, duration of use, and type of hormone. Women who started HRT before age 60 had higher breast cancer risk than those who started after 60. Women who used HRT for ten years or longer had higher risk than those who used it for five years or less.

How combined estrogen-progestin therapy affects breast cancer risk

Combined HRT—estrogen plus progestin taken together—is the most commonly prescribed form because the progestin protects the uterine lining from overgrowth. This combination does increase breast cancer risk, but the increase depends on how long you take it and when you start.

Studies show that breast cancer risk begins to rise after about three to five years of use. The risk is highest in current users and in women who stopped HRT within the past five years. After ten years of stopping HRT, the excess risk largely disappears, though some studies suggest a small elevation may persist longer in certain groups.

The type of progestin matters slightly. Synthetic progestins (like medroxyprogesterone acetate, or MPA) and micronized progesterone appear to carry similar risks in most studies, though some research suggests micronized progesterone may carry a slightly lower risk. The difference is small enough that it should not be the only factor in your decision.

Why estrogen-only therapy has a different risk profile

Women who have had a hysterectomy can take estrogen alone without progestin, because there is no uterine lining to protect. Estrogen-only therapy does not increase breast cancer risk in most studies—in fact, some studies show a slight decrease. However, estrogen alone significantly increases the risk of endometrial cancer (cancer of the uterine lining) in women who still have a uterus, which is why it is not prescribed to them.

Because estrogen-only therapy does not raise breast cancer risk, it may be a reasonable option for women with a history of breast cancer who need symptom relief, though this decision requires discussion with an oncologist. The trade-off is that endometrial cancer risk becomes the concern instead.

Age and timing matter more than you might think

The age at which you start HRT significantly affects your cancer risk. Women who begin HRT before age 60 or within ten years of their final menstrual period show higher breast cancer risk than women who start after age 60. This is partly because younger women have more years ahead of them to develop cancer, and partly because hormone-sensitive breast tissue may be more responsive to hormones in the years immediately after menopause.

A woman who starts HRT at age 55 and takes it for ten years faces a different risk calculation than a woman who starts at age 65 and takes it for five years. Duration matters: the longer you take HRT, the higher your cumulative risk. However, short-term use—typically defined as less than five years—carries a much smaller risk increase than longer-term use.

This is why doctors now often recommend using HRT at the lowest effective dose for the shortest time needed to manage symptoms, rather than as a long-term preventive therapy.

Other health outcomes that factor into the decision

Cancer risk is only one part of the HRT equation. The same WHI study that found increased breast cancer risk also found that HRT reduced hip fractures by about 34 percent and colorectal cancer by about 37 percent. Women taking HRT had fewer bone fractures overall, which matters significantly for women at high risk of osteoporosis.

For cardiovascular health, the picture is more complex. HRT does not prevent heart attacks or strokes in older postmenopausal women, and may slightly increase stroke risk. However, in women who start HRT before age 60 or within ten years of menopause, some cardiovascular benefits may exist. The decision to use HRT often comes down to whether the relief from hot flashes, night sweats, and other menopause symptoms outweighs the modest increase in cancer risk for your particular situation.

Quality of life matters. Severe hot flashes and night sweats can disrupt sleep, work, and relationships. For some women, that burden is greater than the cancer risk they are willing to accept. For others, the risk is unacceptable. There is no single right answer.

What happens to cancer risk after you stop HRT

Breast cancer risk does not stay elevated forever after you stop taking HRT. Studies show that the excess risk begins to decline within a few years of stopping, and by ten years after stopping, the risk returns close to that of women who never took HRT. However, some studies suggest a small elevation may persist longer in certain subgroups, particularly in women who took HRT for very long periods.

This declining risk is one reason doctors now recommend using HRT for the shortest duration needed. If you take HRT for three to five years to manage acute menopause symptoms, your cancer risk elevation is smaller and shorter-lived than if you take it for fifteen years.

Frequently Asked Questions

Does bioidentical hormone therapy carry less cancer risk than synthetic HRT?

Bioidentical hormones—hormones that are chemically identical to those your body makes—are often marketed as safer, but the evidence does not clearly support that claim. The cancer risk appears to depend on the dose and duration of use, not whether the hormones are bioidentical or synthetic. Studies on bioidentical hormones are fewer and smaller than studies on conventional HRT, so less is known about their long-term effects.

If I have a family history of breast cancer, should I avoid HRT entirely?

Family history increases your baseline breast cancer risk, which means HRT adds to an already higher number. However, it does not automatically disqualify you from HRT. The decision depends on how severe your menopause symptoms are, your specific genetic risk (whether you carry a BRCA mutation, for example), and your personal values about risk. This is a conversation to have with your doctor and possibly a genetic counselor.

What about vaginal estrogen or other low-dose forms—do they increase cancer risk?

Vaginal estrogen creams, rings, and tablets deliver hormone directly to vaginal tissue in very small amounts. The systemic absorption is minimal, and studies have not found them to increase breast or endometrial cancer risk. They are generally considered safe for long-term use, even in women with a history of breast cancer, though you should discuss this with your doctor.

How much does my individual cancer risk actually increase if I take HRT?

Your absolute risk depends on your age, family history, and other factors. A 55-year-old woman with no family history of breast cancer has a baseline risk of developing breast cancer by age 65 of roughly 2 to 3 percent. Taking combined HRT for ten years might increase that to 3 to 4 percent. A woman with a strong family history starts from a higher baseline, so the same HRT use adds to a larger number. Your doctor can help estimate your personal risk.

If I stop HRT, will my menopause symptoms come back?

Yes, in many cases they do. Some women find that symptoms have resolved by the time they stop HRT, but others experience a return of hot flashes and night sweats. This is one reason the decision to start HRT involves thinking ahead about how long you plan to use it and what happens when you stop.